Dipeptidylaminopeptidase IV in lymphocytes of patients with lymphoproliferative diseases

1989 ◽  
Vol 108 (1) ◽  
pp. 1005-1007 ◽  
Author(s):  
V. S. Bylinkina ◽  
N. V. Golubeva ◽  
T. A. Gureeva ◽  
L. A. Lokshina ◽  
A. M. Polyanskaya ◽  
...  
Keyword(s):  
Lymphoproliferative Diseases ◽  
Dipeptidylaminopeptidase Iv

scholarly journals Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs

2020 ◽  
Vol 28 (1) ◽  
pp. 159-183
Author(s):  
Vanessa Innao ◽  
Vincenzo Rizzo ◽  
Andrea Gaetano Allegra ◽  
Caterina Musolino ◽  
Alessandro Allegra
Keyword(s):  
Multiple Myeloma ◽  
Hematological Malignancies ◽  
Tumour Cells ◽  
Oncolytic Viruses ◽  
Viral Diseases ◽  
Lymphoproliferative Diseases ◽  
Destructive Effect ◽  
New Class ◽  
Single Mechanism ◽  
Neoplastic Lesions

The use of viruses for tumour treatment has been imagined more than one hundred years ago, when it was reported that viral diseases were occasionally leading to a decrease in neoplastic lesions. Oncolytic viruses (OVs) seem to have a specific tropism for tumour cells. Previously, it was hypothesised that OVs’ antineoplastic actions were mainly due to their ability to contaminate, proliferate and destroy tumour cells and the immediate destructive effect on cells was believed to be the single mechanism of action of OVs’ action. Instead, it has been established that oncolytic viruses operate via a multiplicity of systems, including mutation of tumour milieu and a composite change of the activity of immune effectors. Oncolytic viruses redesign the tumour environment towards an antitumour milieu. The aim of our work is to evaluate the findings present in the literature about the use of OVs in the cure of haematological neoplastic pathologies such as multiple myeloma, acute and chronic myeloid leukaemia, and lymphoproliferative diseases. Further experimentations are essential to recognize the most efficient virus or treatment combinations for specific haematological diseases, and the combinations able to induce the strongest immune response.

Functions of polymorphonuclear (PMN) leukocytes of patients with lymphoproliferative diseases

1985 ◽  
Vol 10 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Shoshana Peller ◽  
Suzana Kaufman ◽  
Rivka Yona
Keyword(s):  
Lymphoproliferative Diseases ◽  
Pmn Leukocytes

scholarly journals Poster: ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry

2021 ◽  
Vol 21 ◽  
pp. S243
Author(s):  
Olga Gavrilina ◽  
Kristina Zakurdaeva ◽  
Anastasia Vasileva ◽  
Vladimir Vorobyev ◽  
Lev Butaev ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Lymphoproliferative Diseases

scholarly journals HCV and lymphoproliferative diseases

1998 ◽  
Vol 9 (5) ◽  
pp. 469-470 ◽  
Author(s):  
C. Trépo ◽  
P. Berthillon ◽  
L. Vitvitski
Keyword(s):  
Lymphoproliferative Diseases
Sign in / Sign up

Export Citation Format

Share Document